Chemours Company (CC) concluded trading on Wednesday at a closing price of $14.62, with 4.8 million shares of worth about $70.13 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -26.57% during that period and on July 23, 2025 the price saw a gain of about 5.10%. Currently the company’s common shares owned by public are about 149.57M shares, out of which, 148.55M shares are available for trading.
Stock saw a price change of 10.34% in past 5 days and over the past one month there was a price change of 37.92%. Year-to-date (YTD), CC shares are showing a performance of -37.73% which decreased to -13.49% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $9.13 but also hit the highest price of $24.50 during that period. The average intraday trading volume for Chemours Company shares is 4.26 million. The stock is currently trading 11.95% above its 20-day simple moving average (SMA20), while that difference is up 24.51% for SMA50 and it goes to -6.15% lower than SMA200.
Chemours Company (NYSE: CC) currently have 149.57M outstanding shares and institutions hold larger chunk of about 97.25% of that.
The stock has a current market capitalization of $2.19B and its 3Y-monthly beta is at 1.60. PE ratio of stock for trailing 12 months is 71.04, while it has posted earnings per share of $0.21 in the same period. Its PEG reads 2.27 and has Quick Ratio of 0.83 while making debt-to-equity ratio of 7.57. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CC, volatility over the week remained 4.20% while standing at 4.83% over the month.
Stock’s fiscal year EPS is expected to rise by 20.37% while it is estimated to increase by 61.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on March 27, 2025 offering an Outperform rating for the stock and assigned a target price of $19 to it. Coverage by Truist stated Chemours Company (CC) stock as a Buy in their note to investors on January 28, 2025, suggesting a price target of $27 for the stock. On July 09, 2024, UBS Upgrade their recommendations, while on June 07, 2024, Mizuho Initiated their ratings for the stock with a price target of $25. Stock get an Outperform rating from BMO Capital Markets on April 09, 2024.
